TABLE 2.
Incidence of drug‐induced pneumonitis
| All patients | Non‐ILD | Pre‐existing ILD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total, n | All‐grade, n (%) | Grade ≥ 3, n (%) | Total, n | All‐grade, n (%) | Grade ≥ 3, n (%) | Total, n | All‐grade, n (%) | Grade ≥ 3, n (%) | |
| 125 | 17 (13.6) | 5 (4.0) | 105 | 7 (6.7) | 2 (1.9) | 20 | 10 (50.0) | 3 (15.0) | |
| Pembrolizumab + platinum + PEM | 65 | 12 (18.5) | 5 (7.7) | 57 | 5 (8.8) | 2 (3.5) | 8 | 7 (87.5) | 3 (37.5) |
| Pembrolizumab + CBDCA + PTX/nab‐PTX | 23 | 1 (4.4) | 0 | 19 | 0 | 0 | 4 | 1 (25.0) | 0 |
| Atezolizumab + CBDCA + PTX + BEV | 29 | 3 (10.3) | 0 | 25 | 2 (8.0) | 0 | 4 | 1 (25.0) | 0 |
| Atezolizumab + CBDCA + nab‐PTX | 8 | 1 (12.5) | 0 | 4 | 0 | 0 | 4 | 1 (25.0) | 0 |
Abbreviations: BEV, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; ILD, interstitial lung disease; nab‐PTX, nanoparticle albumin‐bound paclitaxel; PEM, pemetrexed; PTX, paclitaxel.